-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
On April 19, Ascletis Pharma issued an announcement stating that its oral small molecule drug candidate ASC11 (3CLpro inhibitor) is expected to become an effective drug for the treatment of new coronary pneumonia.
The anti-new coronavirus cell experiment showed that the antiviral activity (EC90) of ASC11 was 31 times (155/5) that of nelmatevir, 120 times (600/5) of S-217622, and 16 times that of PBI-0451 (78/5).
ASC11 is an oral small molecule drug candidate targeting 3CLpro independently developed using proprietary technologies including molecular simulation docking and has global intellectual property rights
Molecular simulation docking technology showed that compared with nematevir, ASC11 formed stronger hydrogen bond interactions with glutamate 166 of 3CLpro, formed new hydrogen bond interactions with other key amino acids of 3CLpro, and interacted with the hydrophobicity of 3CLpro.
In Vero E6 cells, the safety window (cytotoxicity versus antiviral activity) of ASC11 was over 10,000-fold
In addition, Ascletis' second 3CLpro drug candidate showed antiviral activity and safety window consistent with ASC11 in Vero E6 cells
Note: The original text has been deleted
